What Happened?
Shares of healthcare distributor and services company McKesson (NYSE: MCK) jumped 4.4% in the afternoon session after the company reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
The agreement in principle extends the distribution arrangement across CVS Health's retail, mail order, and specialty pharmacies. In addition to the contract extension, the company reaffirmed its fiscal year 2027 adjusted earnings per share forecast of $44.20 to $45.00. McKesson also reiterated its long-term adjusted earnings per share growth rate target of 13% to 16%.
After the initial pop, the shares cooled down to $888.73, up 4.1% from the previous close.
Is now the time to buy McKesson? Access our full analysis report here, it’s free.
What Is The Market Telling Us
McKesson’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock dropped 3.5% on the news that reports revealed that CEO, Brian S. Tyler, sold 8,463 shares of company stock. The sale, valued at approximately $6.7 million, was executed on July 7, 2026, at an average price of $793.56 per share. While the transaction was conducted under a pre-arranged trading plan established in December 2025, a large sale by a top executive can still cause investor concern.
The sharp decline suggests that the news prompted sellers to take control, raising a red flag for some market participants despite what were otherwise considered bullish technical indicators.
McKesson is up 7.9% since the beginning of the year, but at $888.73 per share, it is still trading 10.7% below its 52-week high of $995.69 from March 2026. Investors who bought $1,000 worth of McKesson’s shares 5 years ago would now be looking at an investment worth $4,443.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
